deltatrials
Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05502913

Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer

Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Metastatic Lung Cancer

Sponsor: Biotax Labs LTD

Conditions Metastatic Lung Cancer
Interventions Antibiotics FMT (Fecal Microbiota Transplantation)
Updated 5 times since 2022 Last updated: Sep 27, 2023 Started: Sep 1, 2023 Primary completion: Jun 30, 2025 Completion: Jun 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Lung Cancer, this trial is actively recruiting participants. The trial is conducted by Biotax Labs LTD and has accumulated 5 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2022 – ~Nov 2023 · 14 months · monthly snapshotNot Yet Recruiting~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotRecruiting~Sep 2025 – present · 10 months · monthly snapshotRecruiting

Change History

5 versions recorded

  1. Sep 2025 — Present [monthly]

    Recruiting PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Nov 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Sep 2022 — Nov 2023 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biotax Labs LTD
  • Israel Cancer Association
  • Soroka University Medical Center
Data source: Soroka University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations